Mergen Limited announced it has resolved its patent infringement litigation case with Oxford Gene Technology.  Under the terms of the settlement, Mergen has obtained a license from OGT for its expression chips in the U.S., Europe and Japan.  This license allows Mergen to manufacture and sell microarrays, e.g., Mergen’s ExpressChip(TM) DNA microarray system for high-throughput, high-sensitivity gene expression profiling.   See the Press Release.

Comments are closed.